Health TrialsbyHealthPanel

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

ConditionAmyotrophic Lateral Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-100
SponsorSykehuset Telemark

About this trial

The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Probable or definite ALS

Eligible to consent

Disqualifiers

None

Trial population

Individuals diagnosed with ALS that are being followed through the Norwegian health-care system.

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • Observation

    Other intervention

    Observation of genetic characteristics

Treatment groups

1,200 Participants
are divided into 1 treatment group
Group A: Individuals diagnosed with ALS1 intervention

Trial outcomes

Primary outcomes

1

Gene frequency

Number of patients with disease causing mutations in high penetrant ALS genes

Time frame
2020-2030
2

New ALS genes

Identify new ALS genes in the Norwegian ALS population

Time frame
2024-2030
3

Genetic risk factors

Identify genetic risk factors for ALS in Norway.

Time frame
2022-2030

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sykehuset Telemark

Lead sponsor

ALS Norge

Collaborator

Helse Sor-Ost

Collaborator

Source ClinicalTrials.gov
Apply now